WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer

EMBO Molecular Medicine

Volumn 5, Issue 2, 2013, Pages 264-279

  Wend, Peter ^a   Runke, Stephanie ^a   Wend, Korinna ^a   Anchondo, Brenda ^a   Yesayan, Maria ^a   Jardon, Meghan ^a   Hardie, Natalie ^a   Loddenkemper, Christoph ^b   Ulasov, Ilya ^c   Lesniak, Maciej S ^c   Wolsky, Rebecca ^c   Bentolila, Laurent A ^d   Grant, Stephen G ^e   Elashoff, David ^a   Lehr, Stephan ^f   Latimer, Jean J ^e   Bose, Shikha ^a,g   Sattar, Husain ^c   Krum, Susan A ^a   Miranda Carboni, Gustavo A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

^f BAXTER INNOVATIONS GMBH   (Austria)

^g CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer stem cells; HMGA2; Metastasis; Triple negative breast cancer; Wnt signalling

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HIGH MOBILITY GROUP A2 PROTEIN; PROGESTERONE RECEPTOR; WNT10B PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BASAL AMYGDALA; BREAST DEVELOPMENT; BREAST METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; UPREGULATION;

ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; UP-REGULATION; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84873283904     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201201320     Document Type: Article

References (46)

1. Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA (2010) Protein expression profile and prevalence pattern of the molecular classes of breast cancer-a Saudi population based study. BMC Cancer 10: 1-13.
2. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
4. Cowin P, Rowlands TM, Hatsell SJ (2005) Cadherins and catenins in breast cancer. Curr Opin Cell Biol 17: 499-508.
5. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A, et al (2009) HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 69: 1844-1850.
6. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, et al (2004) A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 101: 12682-12687.
7. Fedele M, Pierantoni GM, Visone R, Fusco A (2006) E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 1: 17.
8. Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev 7: 899-910.
9. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS (2011) Beta-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231.
10. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res Treat 123: 725-731.
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
12. Huelsken J, Vogel R, Brinkmann V, Erdmann B, Birchmeier C, Birchmeier W (2000) Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol 148: 567-578.
13. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920.
14. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev 8: 387-398.
15. Klemm F, Bleckmann A, Siam L, Chuang HN, Rietkotter E, Behme D, Schulz M, Schaffrinski M, Schindler S, Trumper L, et al (2011) Beta-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis 32: 434-442.
16. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (2008a) Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27: 535-545.
17. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M (2008b) Unique ERalpha cistromes control cell type-specific gene regulation. Mol Endocrinol 22: 2393-2406.
18. Latimer JJ, Johnson JM, Kelly CM, Miles TD, Beaudry-Rodgers KA, Lalanne NA, Vogel VG, Kanbour-Shakir A, Kelley JL, Johnson RR, et al (2010) Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. Proc Natl Acad Sci USA 107: 21725-21730.
19. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
20. Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano L, Jass JR (2007) Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology 50: 453-464.
21. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, et al (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22: 1184-1193.
22. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723-2735.
23. Martensson A, Oberg A, Jung A, Cederquist K, Stenling R, Palmqvist R (2007) Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep 17: 447-452.
24. Micci F, Teixeira MR, Heim S (2001) Complete cytogenetic characterization of the human breast cancer cell line MA11 combining G-banding, comparative genomic hybridization, multicolor fluorescence in situ hybridization, RxFISH, and chromosome-specific painting. Cancer Genet Cytogenet 131: 25-30.
25. Miranda-Carboni GA, Krum SA, Yee K, Nava M, Deng QE, Pervin S, Collado-Hidalgo A, Galic Z, Zack JA, Nakayama K, et al (2008) A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev 22: 3121-3134.
26. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
27. Nusse R (2005) Wnt signaling in disease and in development. Cell Res 15: 28-32.
28. Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125: 627-636.
29. Peluso S, Chiappetta G (2010) High-mobility group A (HMGA) proteins and breast cancer. Breast Care (Basel) 5: 81-85.
30. Perou CM (2010) Molecular stratification of triple-negative breast cancers. Oncologist 15 (Suppl. 5): 39-48.
31. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
32. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev 9: 265-273.
33. Reeves R (2000) Structure and function of the HMGI(Y) family of architectural transcription factors. Environ Health Perspect 108 (Suppl. 5): 803-809.
34. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J (1997) Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 19: 153-156.
35. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423.
36. Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, Lane TF (2010) Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 25: 2138-2147.
37. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439: 993-997.
38. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, Cowin P (2009) MMTV-Wnt1 and -DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS ONE 4: e4537.
39. Tessari MA, Gostissa M, Altamura S, Sgarra R, Rustighi A, Salvagno C, Caretti G, Imbriano C, Mantovani R, Del Sal G, et al (2003) Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 23: 9104-9116.
40. Veltmaat JM, Van Veelen W, Thiery JP, Bellusci S (2004) Identification of the mammary line in mouse by Wnt10b expression. Dev Dyn 229: 349-356.
41. Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6: 718-730.
42. Wend P, Holland JD, Ziebold U, Birchmeier W (2010) Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 21: 855-863.
43. Wend P, Wend K, Krum SA, Miranda-Carboni GA (2011) The role of WNT10B in physiology and disease. Acta Physiol (Oxf) 204(1): 34-51.
44. Wend P, Anchondo B, Wend K, Krum SA, Miranda-Carboni GA (2012) The Role of WNT10B/β-catenin signaling and HMGA2 in lung metastasis EMBO Conference 30 Years of Wnt Signaling, 2012, Netherlands.
45. Wong SC, Lo ES, Chan AK, Lee KC, Hsiao WL (2003) Nuclear beta catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong. Mol Pathol 56: 347-352.
46. Zhou X, Benson KF, Ashar HR, Chada K (1995) Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376: 771-774.